Patents by Inventor Olivier Alexis Georges Querolle
Olivier Alexis Georges Querolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240417405Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: ApplicationFiled: May 6, 2022Publication date: December 19, 2024Inventors: Olivier Alexis Georges Querolle, Xuedong Dai, Wei Cai, Johannes Wilhelmus J. Thuring, Lichao Fang, Ming Li, Lianzhu Liu, Yingtao Liu, Luoheng Qin, Jianping Wu, Yanping Xu, Patrick Rene Angibaud, Helene France Solange Colombeo, Isbelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Carsten Sven Kramer, Vineet Pande, Xiangjun Deng
-
Patent number: 12084462Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: GrantFiled: November 29, 2021Date of Patent: September 10, 2024Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
-
Publication number: 20240261292Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.Type: ApplicationFiled: May 9, 2022Publication date: August 8, 2024Inventors: Nikki Daskalakis, Christina Diane Guttke, Min Chul Kwon, Lucille Angela Ferrante, Kathryn Elizabeth Packman, Eva Christine Pietsch, Ulrike Philippar, Tinne Ann J. Verhulst, Sumia Ali-Ahmed, Balpreet Bhogal, Yu Sun, Wei Cai, Xuedong Dai, Olivier Alexis Georges Querolle, Johannes Wilhelmus J. Thuring, Yingtao Liu, Lianzhu Liu, Yanping Xu, Liqiang Fu, Ming Li, Lichao Fang, Xiangjun Deng, Alicia Tee Fuay Ng, Nicolas Freddy J. Darville, Vineet Pande
-
Publication number: 20230250096Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.Type: ApplicationFiled: May 30, 2022Publication date: August 10, 2023Inventors: Wei Cai, Johannes Wilhelmus J. Thuring, Fabian Hulpia, Xuedong Dai, Ming Li, Xiangjun Deng, Chao Liang, Alicia Tee Fuay Ng, Zhen Sun, Zhigao Zhang, Samuel Dominique Demin, Natalia Nikolaevna Dyubankova, Matthiew Dominique Jouffroy, Susan Lepri, Nicolas Freddy J. Darville, Vineet Pande, Wim Bert Griet Schepens, James Patrick Edwards, Olivier Alexis Georges Querolle
-
Publication number: 20230203011Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: December 19, 2022Publication date: June 29, 2023Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
-
Publication number: 20230039917Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: ApplicationFiled: May 2, 2022Publication date: February 9, 2023Inventors: Xuedong DAI, Olivier Alexis Georges QUEROLLE, Daniel Jason KROSKY, Wei CAI, Liqiang FU, Linglong KONG, Yingtao LIU, Zhao-Kui WAN, Barbara MORSCHHÄUSER GEB. HERKERT, Vineet PANDE, James Patrick EDWARDS, Aaron Nathaniel PATRICK, Patrick René ANGIBAUD, Virginie Sophie PONCELET
-
Patent number: 11542247Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: September 22, 2016Date of Patent: January 3, 2023Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
-
Patent number: 11530226Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: GrantFiled: July 17, 2020Date of Patent: December 20, 2022Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
-
Patent number: 11396517Abstract: Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: GrantFiled: December 19, 2018Date of Patent: July 26, 2022Assignee: Janssen Pharmaceutica NVInventors: Xuedong Dai, Olivier Alexis Georges Querolle, Daniel Jason Krosky, Wei Cai, Liqiang Fu, Linglong Kong, Yingtao Liu, Zhao-Kui Wan, Barbara Morschhäuser Geb. Herkert, Vineet Pande, James Patrick Edwards, Aaron Nathaniel Patrick, Patrick René Angibaud, Virginie Sophie Poncelet
-
Publication number: 20220227786Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: ApplicationFiled: November 29, 2021Publication date: July 21, 2022Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
-
Publication number: 20220135544Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: October 20, 2021Publication date: May 5, 2022Applicant: ASTEX THERAPEUTICS LTDInventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
-
Patent number: 11267804Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: November 12, 2019Date of Patent: March 8, 2022Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
-
Patent number: 11236084Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: July 4, 2018Date of Patent: February 1, 2022Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Calum Macleod, Samuel Edward Mann, Janusz Jozef Kulagowski, Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel
-
Patent number: 11220517Abstract: The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.Type: GrantFiled: September 13, 2017Date of Patent: January 11, 2022Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
-
Patent number: 11186589Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11180487Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: January 20, 2017Date of Patent: November 23, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
-
Patent number: 11155555Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: September 22, 2016Date of Patent: October 26, 2021Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Helene France Solange Colombel, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
-
Patent number: 11136311Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: June 29, 2017Date of Patent: October 5, 2021Assignee: Janssen Pharmaceutica NVInventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
-
Patent number: 11130751Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: March 29, 2018Date of Patent: September 28, 2021Assignee: Janssen Pharmaceutica NVInventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
-
Publication number: 20210188840Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoinmmune disorders.Type: ApplicationFiled: July 4, 2018Publication date: June 24, 2021Inventors: George HYND, Calum MACLEOD, Samuel Edward MANN, Janusz Jozef KULAGOWSKI, Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL
